Simcere Pharmaceutical Group Limited (FRA:S2P)

Germany · Delayed Price · Currency is EUR

1.210

+0.040 (3.42%)

At close: Oct 23, 2026

Market Cap	3.13B -15.3%
Revenue (ttm)	1.12B +22.8%
Net Income	202.52M +81.4%
EPS	0.08 +73.0%
Shares Out	n/a
PE Ratio	15.13
Forward PE	13.17
Dividend	0.02 (1.88%)
Ex-Dividend Date	Jun 17, 2026

Volume	n/a
Open	1.210
Previous Close	1.170
Day's Range	1.210 - 1.210
52-Week Range	1.000 - 1.560
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About FRA:S2P

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Rα; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clini... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1995

Employees 7,064

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol S2P

Financial Performance

In 2025, FRA:S2P's revenue was 7.73 billion, an increase of 16.52% compared to the previous year's 6.64 billion. Earnings were 1.34 billion, an increase of 86.15%.

Financial numbers in CNY Financial Statements